FDA accepts BioMarin's application for full approval of achondroplasia drug

July 13, 2026 9:05 AM

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the U.S. Food and Drug Administration has accepted the company's supplemental New Drug ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found